News

SERMONIX RECEIVES TWO AWARDS AT THE NORTH AMERICAN MENOPAUSE SOCIETY ANNUAL MEETING

Research on the Company’s Investigational Drug, Lasofoxifene, Takes First Place Among Scientific Posters COLUMBUS, OH (October 7, 2015) – Sermonix Pharmaceuticals LLC, a specialty pharmaceutical company focused on the development and commercialization of emerging late-stage women’s health products, today announced it received top honors for its research on investigational drug lasofoxifene at [...]
Read more

Sermonix Pharmaceuticals To Present Three Lasofoxifene Papers And One Poster At The North American Menopause Society

Company to Share Results from Studies of Investigational Drug, Lasofoxifene COLUMBUS, OH (September 16, 2015) – Sermonix Pharmaceuticals LLC, a specialty pharmaceutical company focused on the development and commercialization of emerging late-stage women’s health products, announced today that experts and researchers will provide three presentations and a poster about its investigational [...]
Read more
2015-clc-logo-1

Sermonix joins the 2015 NAMS Corporate Liaison Council

The North American Menopause Society (NAMS) is the leading nonprofit scientific organization dedicated to promoting the health and quality of life of all women during midlife and beyond through an understanding of menopause and healthy aging. Join us at the NAMS 2015 Annual Meeting (September 30 through October 3) at the Caesars Palace Hotel in […]
Read more

Sermonix Pharmaceuticals Convenes Scientific Advisory Board

COLUMBUS, OH — (Marketwired) — 07/23/15 — Sermonix Pharmaceuticals LLC, a specialty pharmaceutical company focused on the development and commercialization of emerging late-stage women’s health products, recently convened the inaugural meeting of its Scientific Advisory Board. The board, which includes leading multidisciplinary experts in selective estrogen receptor [...]
Read more

The Sermonix Scientific Advisory Board meets at Inn Walden, Aurora, Ohio June 11th and 12th

The Sermonix Scientific Advisory Board meets at Inn Walden, Aurora, Ohio June 11th and 12th to discuss lasofoxifene and women’s menopausal health issues. The group, composed of some of the world’s leading experts in selective estrogen receptor modulators, hormone therapy, osteoporosis, VVA and breast cancer will analyze lasofoxifene clinical data. Resubmission and [...]
Read more

Ligand Signs License Agreement with Sermonix for Lasofoxifene

SAN DIEGO, Feb 03, 2015 (BUSINESS WIRE) — Ligand Pharmaceuticals Incorporated announces the signing of a license agreement with Sermonix Pharmaceuticals LLC for the development and commercialization of oral lasofoxifene in the United States and additional territories. Under the terms of the agreement, Ligand has received an undisclosed initial payment, and is entitled to receive […]
Read more